Stereoselectivity of idarubicin reduction in various animal species and humans

References

• Ahmed N. K., Felsted R. L., Bachur N. R. Heterogeneity of anthracycline antibiotic carbonyl reductases in mammalian livers. Biochemical Pharmacology 1978; 27: 2713–2719
   PubMed Web of Science ®Google Scholar
• Arcamone F., Bernardi L., Giardino P., Patelli B., Di Marco A., Casazza A. M., Pratesi G., Reggiani P. Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their β anomers. Cancer Treatment Reports 1976; 60: 829–834
   PubMedGoogle Scholar
• Broadhurst M. J., Hassall C. H., Thomas G. J. The total synthesis of 13(R)- and 13(S)-dihydro-4-demethoxydaunorubicin. Revision of stereochemistry of the microbial and mammalian reduction product of 4-demethoxydaunorubicin. Tetrahedron Letters 1984; 25: 6059–6062
   Google Scholar
• Broggini M., Sommacampagna B., Paolini A., Dolfini E., Donelli M. G. Comparative metabolism of daunorubicin and 4-demethoxydaunorubicin in mice and rabbits. Cancer Treatment Reports 1986; 70: 697–702
   PubMedGoogle Scholar
• Bachur N. R. Cytoplasmic aldo-keto reductases: a class of drug metabolizing enzymes. Sciences 1976; 193: 595–597
   PubMed Web of Science ®Google Scholar
• Bachur N. R. Anthracycline antibiotic pharmacology and metabolism. Cancer Treatment Reports 1979; 63: 817–820
   PubMedGoogle Scholar
• Carella A. M., Santini G., Martinengo M., Giordano D., Nati S., Congiu A., Cerri R., Risso M., Damasio E., Rossi E., Vimercati R., Pacciarini M. A., Marmont A. M. 4-Demethoxydaunorubicin (idarubicin) in refractory or relapsed acute leukemias. Cancer 1985; 55: 1452–1454
   PubMed Web of Science ®Google Scholar
• Casazza A. M., Barbieri B., Fumagalli A., Geroni M. C. Biologic activity of 4-demethoxy-13-dihydrodaunorubicin. Proceedings of the American Association for Cancer Research 1983; 24: 251
   Web of Science ®Google Scholar
• Cassinelli G., Grein A., Merli S., Penco S., Rivola G., Vigevani A., Zini P., Arcamone F. Microbial and mammalian stereoselective conversion of 4-demethoxydaunorubicin to the corresponding 13-(R)-dihydro derivative. Gazzetta Chimica Italiana 1984a; 114: 185–188
   Google Scholar
• Cassinelli G., Configliacchi E., Penco S., Rivola G., Arcamone F., Pacciarini A., Ferrari L. Separation, characterization, and analysis of epirubicin (4′-epidoxorubicin) and its metabolites from human urine. Drug Metabolism and Disposition 1984b; 12: 506–510
   PubMedGoogle Scholar
• Culp H. W., McMahon R. E. Reductase for aromatic aldehydes and ketones. Journal of Biological Chemistry 1968; 243: 848–852
   PubMed Web of Science ®Google Scholar
• Di Marco A., Casazza A. M., Pratesi G. Antitumor activity of 4-demethoxydaunorubicin administered orally. Cancer Treatment Reports 1977; 61: 893–894
   PubMedGoogle Scholar
• Felsted R. L., Bachur N. R. Mammalian carbonyl reductases. Drug Metabolism Reviews 1980; 11: 1–60
   PubMed Web of Science ®Google Scholar
• Felsted R. L., Bachur N. R. Human liver daunorubicin reductases. Progress in Clinical and Biological Research 1982; 114: 291–305
   PubMedGoogle Scholar
• Felsted R. L., Gee M., Bachur N. R. Rat liver daunorubicin reductase. Journal of Biological Chemistry 1974; 249: 3672–3679
   PubMed Web of Science ®Google Scholar
• Felsted R. L., Richter D. R., Jones D. M., Bachur N. R. Isolation and characterization of rabbit liver xenobiotic carbonyl reductases. Biochemical Pharmacology 1980; 29: 1503–1516
   PubMed Web of Science ®Google Scholar
• Le Bot M. A., Bégué J. M., Kernaleguen D., Robert J., Ratanasavanh D., Airiau J., Riché C., Guillouzo A. Different cytotoxicity and metabolism of doxorubicin, duanorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes. Biochemical Pharmacology 1988; 37: 3877–3887
   PubMed Web of Science ®Google Scholar
• Loveless H., Arena E., Felsted R. L., Bachur N. R. Comparative mammalian metabolism of adriamycin and daunorubicin. Cancer Research 1978; 38: 593–598
   PubMed Web of Science ®Google Scholar
• Maessen P. A., Mross K. B., Pinedo H. M., van Der Vijgh W. J. F. Metabolism of epidoxorubicin in animals: absence of glucuronidation. Cancer Chemotherapy and Pharmacology 1987; 20: 85–87
   PubMedGoogle Scholar
• Martoni A., Pacciarini M. A., Pannuti F. Activity of 4-demethoxydaunorubicin by the oral route in advanced breast cancer. European Journal of Cancer & Clinical Oncology 1985; 21: 803–806
   PubMedGoogle Scholar
• McMahon R. E. Alcohols, aldehydes, and ketones. Metabolic Basis of Detoxication, W. Jacoby, J. Bend, J. Caldwell. Academic Press, New York 1982; 91–104
   Google Scholar
• Moreland T. A., Hewick D. S. Studies on a ketone reductase in human and rat liver and kidney soluble fraction using warfarin as a substrate. Biochemical Pharmacology 1975; 24: 1953–1957
   PubMed Web of Science ®Google Scholar
• Moro E., Bellotti V., Jannuzzo M. G., Stegnjaich S., Valzelli G. High-performance liquid chromatographic method for pharmacokinetic studies on the new anthracycline 5- demethoxydaunorubicin and its 13-dihydro derivative. Journal of Chromatography Biomedical Applications 1983; 274: 281–287
   PubMed Web of Science ®Google Scholar
• Penco S., Cassinelli G., Vigevani A., Zini P., Rivola G., Arcamone F. Daunorubicin aldo-keto reductases: enantioface differential reduction of the side-chain carbonyl group of antitumor anthracyclines. Correction of the stereochemistry at C(13) of 4-demethoxy-13- dihydrodaunorubicin. Gazzetta Chimica Italiana 1985; 115: 195–197
   Google Scholar
• Takanashi S., Bachur R. N. Adriamycin metabolism in man. Evidence from urinary metabolites. Drug Metabolism and Disposition 1976; 4: 79–87
   PubMed Web of Science ®Google Scholar
• Turner A. J., Hick P. E. Metabolism of daunorubicin by a barbiturate-sensitive aldehyde reductase from rat liver. Biochemical Journal 1976; 159: 819–822
   PubMed Web of Science ®Google Scholar
• Weil A., Caldwell J., Strolin Benedetti M., Dostert P. Species differences in the metabolic disposition of fenofibrate. Drugs Affecting Lipid Metabolism, R. Paoletti, D. Kritchevsky, W. L. Holmes. Springer-Verlag, Berlin 1987; 324–327
   Google Scholar
• Young R. C., Ozols R. F., Myers C. E. The anthracycline antineoplastic drugs. The New England Journal of Medicine 1981; 305: 139–153
   PubMed Web of Science ®Google Scholar
• Zini G., Vicario G. P., Lazzati M., Arcamone F. Disposition and metabolism of [14-14C]4-demethoxydaunorubicin HCl (idarubicin) and [14-14C]daunorubicin HCl in the rat. Cancer Chemotherapy and Pharmacology 1986; 16: 107–115
   PubMed Web of Science ®Google Scholar